Download PDF
Thromb Haemost 2000; 84(03): 522-523
DOI: 10.1055/s-0037-1614059
Letters to the Editor
Schattauer GmbH

rFVIIa – Its Thrombogenicity

L. M. Aledort
1   From The Mount Sinai School of Medicine, New York, USA
› Author AffiliationsThis study was supported in part by Health Services Administration Grant MCB-360001; Health and Human Services Grant HS-30567; the Regional Comprehensive Hemophilia Diagnostic and Treatment Center; the Margie Boas Fund; the International Hemophilia Training Center of the World Federation of Hemophilia; the Polly Annenberg Levee Hematology Center, Department of Medicine, Mount Sinai School of Medicine of the City University of New York; and grant 5MO1RR00071 for the Mount Sinai General Clinical Research Center from the National Center for Research Resources, National Institutes of Health.
Further Information

Publication History

Received 29 February 2000

Accepted 03 March 2000

Publication Date:
14 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Hilgartner M, Aledort L, Andes A, Gill J. and the members of the FEIBA Study Group. Efficacy and Safety of Vapor-Heated Anti-Inhibitor Coagulant Complex in Hemophilia Patients. Transfusion 1990; 30: 626-30.
    CrossrefPubMedGoogle Scholar
  • 2 Peerlinck K, Vermylen J. Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor. Thromb Haemost 1999; 82: 1775-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Kerwood FR. Novo Nordisk (June 16,1995): Dear Doctor, letter to inform US investigators following FDA requirements.
    PubMed
  • 4 Hedner U, Glazer S, Faich J. Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients with Inherited and Acquired Bleeding Disorders. Trans Med Rev 1993; 07: 78-83.
    CrossrefPubMedGoogle Scholar
  • 5 d’Oiron R, Ménart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Negrier C. Recombinant factor VIIa in Glanzmann’s thrombasthenia: A potential therapeutic place. Thromb Heamost 2000; 83: 644-7.
    PubMedGoogle Scholar
  • 6 Schulman S. for the rFVIIa-CI Group. Safety, Efficacy and Lessons from Continuous Infusion with rFVIIa. Haemophil 1998; 04: 564-7.
    PubMedGoogle Scholar
  • 7 Juvonen E, Kolho E, Anttila VJ, Lommi J, Nissinen M, Rasi V. Helsinki University Central Hospital, Clinic of Internal Medicine, Central Hospital of Mikkeli, FRC Blood Transfusion Service, Helsinki, Finland. Acute Myocardial Infarction Complicating Therapy with FVIII followed by APCC and rFVIIa in a 26-Year-Old Man with Haemophilia A and FVIII Inhibitor. Haemophil 1998; 04: 338 (Abstract).
    PubMedGoogle Scholar
  • 8 Clinical experience with NovoSeven: Summary of efficacy and safety. August 1996
    PubMedGoogle Scholar
  • 9 European public assessment report on NovoSeven. 1996; 28: 10.
    PubMed
  • 10 Turecek PL, Richter G, Muchitson EM, Pichler L, Schwarz HP, Morrissey J. Thrombogenicity of recombinant factor VIIa and recombinant soluble tissue factor in an in vivo rabbit model. Thromb Haemostas Abstracts; XVIth Congress of the International Society of Thrombosis and Haemostasis, Florence, Italy. June 6-12,1997; PS903: 222.
    PubMedGoogle Scholar